Cell therapy
for every
patient in need
Automating the manufacture of CAR T-cells
What we do
CAR T-cell therapy is transformative
But complex logistics, lack of standardised manufacturing processes and high costs limit access to CAR-T therapies to combat cancer, which in turn limits the commercial success of these life-changing innovations.
BioOra addresses both access and scale issues by providing an affordable and accelerated pathway to market for CAR-T therapies via lower cost, high throughput, GMP licensed manufacturing capabilities from clinical trial through to registration and commercialisation.
Automated GMP compliant manufacturing process
Shorter vein-to-vein timeline
Lower production costs
Speed up your path to patients with BioOra
Higher treatment capacity
Internationally compliant CMC dossier for registration
Why BioOra?
Dedicated GMP Labs
Our GMP-certified, state-of-the-art suite of labs are purpose-designed for production of clinical grade CAR-T cellular therapies.
End-to-end automation
We use the industry-leading LONZA Cocoon® platform for automated, closed and controlled manufacture of patient-scale CAR T cells.
World-class expertise
Our scientists work with you to create a rigorous, regulated and tailored approach to your CAR-T therapy manufacturing needs.
Quality control
Our quality control team monitors and tests samples throughout the entirety of the CAR-T therapy manufacturing process ensuring quality remains uncompromised.
Regulatory advisors
Our unmatched experience working with regulatory bodies will help you navigate the regulatory landscape within New Zealand.
“It is exciting to make this transformative therapy accessible to patients from around the world and be a part of bringing new CAR T cell products to the clinic.”
— Saum Vahdat, Director